From Our 2012 Archives
Drug Approved to Prevent Respiratory Distress Syndrome
WEDNESDAY, March 7 (HealthDay News) -- Sufaxin (lucinacant) has been approved by the U.S. Food and Drug Administration to prevent respiratory distress syndrome, a serious lung condition that affects infants born prematurely.
Latest Lungs News
Premature birth is defined as being born before 37 weeks' gestation. The lungs of infants born this early can't produce surfactant, a liquid that coats the lungs and prevents them from collapsing. Most babies with respiratory distress syndrome show signs of breathing problems within the first hours after birth, the FDA said in a news release.
Sufaxin, the fifth FDA-approved drug for respiratory distress syndrome, was evaluated in clinical studies involving nearly 1,300 premature infants. Most side effects involved the breathing tube used to administer the drug. Adverse reactions included tube reflux or obstruction, skin paleness and the need for dose interruption.
Sufaxin is produced by Discovery Laboratories, of Warrington, Penn.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions